MXRA8 and neoplasm: Consistent with the result of HT29 cells, OVM reached a better therapeutic efficacy in HeLa and HepG2 tumors with MXRA8 expressing, and the total tumor weight was significantly reduced in MXRA8-expressing group treated with OVM compared to MXRA8-deficient group (Fig. 2j–o).